RECURSION PHARMACEUTICALS, INC. Research and Development Expense
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Research and Development Expense of $89.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $89.61M, a 30.34% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $87.90M, a 32.20% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $95.94M, a 2.43% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $121.06M, a 62.28% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $475.27M, a 51.16% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $314.42M, a 30.34% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $241.23M, a 54.93% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $155.70M, a 15.10% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.61M 10-Q · filed 2026-08-05 | $177.51M 10-Q · filed 2026-08-05 | $273.45M derived: sum of 3 quarters · filed 2026-08-05 | $394.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $87.90M 10-Q · filed 2026-05-06 | $183.84M derived: sum of 2 quarters · filed 2026-05-06 | $304.90M derived: sum of 3 quarters · filed 2026-05-06 | $433.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $95.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $217.00M derived: sum of 2 quarters · filed 2026-02-25 | $345.64M derived: sum of 3 quarters · filed 2026-08-05 | $475.27M 10-K · filed 2026-02-25 |
| 2025-09-30 | $121.06M 10-Q · filed 2025-11-05 | $249.70M derived: sum of 2 quarters · filed 2026-08-05 | $379.33M 10-Q · filed 2025-11-05 | $477.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $128.64M 10-Q · filed 2026-08-05 | $258.27M 10-Q · filed 2026-08-05 | $356.60M derived: sum of 3 quarters · filed 2026-08-05 | $431.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $129.63M 10-Q · filed 2026-05-06 | $227.97M derived: sum of 2 quarters · filed 2026-05-06 | $302.57M derived: sum of 3 quarters · filed 2026-05-06 | $376.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $98.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $172.93M derived: sum of 2 quarters · filed 2026-02-25 | $246.86M derived: sum of 3 quarters · filed 2026-02-25 | $314.42M 10-K · filed 2026-02-25 |
| 2024-09-30 | $74.60M 10-Q · filed 2025-11-05 | $148.53M derived: sum of 2 quarters · filed 2025-11-05 | $216.09M 10-Q · filed 2025-11-05 | $285.57M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $73.93M 10-Q · filed 2025-08-05 | $141.49M 10-Q · filed 2025-08-05 | $210.97M derived: sum of 3 quarters · filed 2026-02-25 | $280.98M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $67.56M 10-Q · filed 2025-05-05 | $137.04M derived: sum of 2 quarters · filed 2026-02-25 | $207.05M derived: sum of 3 quarters · filed 2026-02-25 | $262.11M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $69.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $139.49M derived: sum of 2 quarters · filed 2026-02-25 | $194.55M derived: sum of 3 quarters · filed 2026-02-25 | $241.23M 10-K · filed 2026-02-25 |
| 2023-09-30 | $70.01M 10-Q · filed 2024-11-06 | $125.07M derived: sum of 2 quarters · filed 2024-11-06 | $171.74M 10-Q · filed 2024-11-06 | $215.72M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $55.06M 10-Q · filed 2024-08-08 | $101.74M 10-Q · filed 2024-08-08 | $145.72M derived: sum of 3 quarters · filed 2025-02-28 | $186.55M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $46.68M 10-Q · filed 2024-05-09 | $90.66M derived: sum of 2 quarters · filed 2025-02-28 | $131.49M derived: sum of 3 quarters · filed 2025-02-28 | $169.93M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $43.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $84.82M derived: sum of 2 quarters · filed 2025-02-28 | $123.25M derived: sum of 3 quarters · filed 2025-02-28 | $155.70M 10-K · filed 2025-02-28 |
| 2022-09-30 | $40.84M 10-Q · filed 2023-11-09 | $79.28M derived: sum of 2 quarters · filed 2023-11-09 | $111.72M 10-Q · filed 2023-11-09 | $160.01M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $38.44M 10-Q · filed 2023-08-08 | $70.88M 10-Q · filed 2023-08-08 | $119.17M derived: sum of 3 quarters · filed 2024-02-29 | $152.42M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $32.44M 10-Q · filed 2023-05-08 | $80.73M derived: sum of 2 quarters · filed 2024-02-29 | $113.98M derived: sum of 3 quarters · filed 2024-02-29 | $143.60M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $48.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $81.54M derived: sum of 2 quarters · filed 2024-02-29 | $111.16M derived: sum of 3 quarters · filed 2024-02-29 | $135.27M 10-K · filed 2024-02-29 |
| 2021-09-30 | $33.25M 10-Q · filed 2022-11-08 | $62.87M derived: sum of 2 quarters · filed 2022-11-08 | $86.98M 10-Q · filed 2022-11-08 | $107.68M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $29.62M 10-Q · filed 2022-08-09 | $53.73M 10-Q · filed 2022-08-09 | $74.43M derived: sum of 3 quarters · filed 2023-02-27 | $90.97M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $24.11M 10-Q · filed 2022-05-10 | $44.81M derived: sum of 2 quarters · filed 2023-02-27 | $61.34M derived: sum of 3 quarters · filed 2023-02-27 | $74.59M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $20.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $37.23M derived: sum of 2 quarters · filed 2023-02-27 | $50.48M derived: sum of 3 quarters · filed 2023-02-27 | $63.32M 10-K · filed 2023-02-27 |
| 2020-09-30 | $16.54M 10-Q · filed 2021-11-10 | $29.78M derived: sum of 2 quarters · filed 2021-11-10 | $42.62M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $13.24M 10-Q · filed 2021-08-13 | $26.09M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $12.84M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $45.81M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |